# BreezeBio

BreezeBio is an Asset Manager based in South San Francisco, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** South San Francisco, United States
- **Region:** North America
- **Address:** South San Francisco, California, United States
- **Assets under management:** Undisclosed
- **Website:** www.genedit.com
- **LinkedIn:** https://www.linkedin.com/company/genedit

## Regulatory record

- **Reports private funds:** No

## About

GenEdit, a biotechnology firm based in Brisbane, United States, was founded in 2016. The company focuses on developing therapies through targeted delivery of genetic medicines. GenEdit has secured $118.5 million in total funding.

## Sectors

- Biotech
- Genetic Medicine

## Offices

- South Korea

## People

- Ryan Lee — Chief Executive Officer & Co-founder
- Huey Park — Chief Operating Officer & Co-founder
- Niren Murthy — Co-founder & Professor at UC Berkeley
- J. Rodrigo Mora — Chief Scientific Officer
- Dong Kim — Chief Business Officer
- SJ Kim — Chief Strategy Officer
- Jeff Kang — Chief Financial Officer
- Derek Sloan — Senior VP of Research
- Steven Bodovitz — VP of Corporate Strategy

## Questions

### Who runs investment decisions at BreezeBio?

Ryan Lee, CEO and co-founder, leads corporate strategy. The executive team also includes Chief Scientific Officer J. Rodrigo Mora, formerly VP of Immunoengineering at Moderna, and Chief Business Officer Dong Kim, who previously led business development at Mirum Pharmaceuticals and Aduro Biotech. The board includes investors from Sequoia, Eli Lilly, and Korea Investment, who provide oversight on capital allocation.

### How does BreezeBio source proprietary technology?

BreezeBio's core platform, NanoGalaxy, was developed in-house at UC Berkeley by co-founders Lee, Park, and Murthy. The company uses AI-directed screening to optimize nanoparticle formulations for cell-specific delivery, covering mRNA, CRISPR ribonucleoproteins, and pDNA. It holds multiple patents on polymer-based nanoparticle compositions and has disclosed collaborations with Genentech and Sarepta Therapeutics to apply its platform to specific disease areas.

### Does BreezeBio participate in fund commitments or only direct deals?

BreezeBio is a product-based biotech company, not an investment firm. It does not make fund commitments. It operates as a single-entity developer of genetic medicines, raising equity financing from institutional investors to fund its internal pipeline and platform development.

### What investment stages does BreezeBio typically target?

BreezeBio is a development-stage company, not a stage-based investor. It is currently advancing preclinical and clinical programs, with its lead candidate BRZ-101 for Type 1 Diabetes in preclinical development. It has not yet entered clinical trials.

### Which sectors does BreezeBio explicitly avoid?

BreezeBio focuses exclusively on genetic medicine delivery and has no disclosed diversification into other sectors. It avoids small-molecule drugs, traditional biologics, and medical devices. Its pipeline centers on autoimmune disease and oncology, with no announced plans in common biotech areas like infectious disease or vaccines.

### How is BreezeBio related to its prior name GenEdit?

BreezeBio was formerly known as GenEdit. The company rebranded in early 2026 as part of its Series B announcement (per firm press release, February 2026). The legal entity, ownership structure, and management team remained the same; the name change reflects a strategic pivot toward autoimmune disease and the BreezeBio branding.

## Related profiles

- [Creyon Bio](https://altss.com/profile/creyon-bio)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/genedit

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology